Can-Fite Biopharma Ltd Sponsored stock is up 6.42% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.36% of the previous 10 December’s closed higher than November.
Can-Fite BioPharma Ltd. develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the. treatment of psoriasis; and Phase II clinical trials for COVID-19. It also develops Namodenoson that is in Phase III. trial for. hepatocellular carcinoma, as well as in Phase IIb trial for treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial.